Methods and compositions involving miRNA and miRNA inhibitor molecules
First Claim
Patent Images
1. A method for reducing cell viability of human cancer cells comprising providing miRNA function to the cells by introducing into the cells a synthetic double-stranded RNA molecule 22-30 residues in length comprising:
- a) an active strand comprising a sequence identical to human miR-34a andb) a separate complementary strand comprising a sequence that is 100% complementary to the human miR-34a sequence and at least one chemical modification at the 5′
end that enhances uptake of the active strand,wherein the human cancer cells are lung cancer cells, cancerous T cells, prostate cancer cells, or skin cancer cells.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
295 Citations
17 Claims
-
1. A method for reducing cell viability of human cancer cells comprising providing miRNA function to the cells by introducing into the cells a synthetic double-stranded RNA molecule 22-30 residues in length comprising:
-
a) an active strand comprising a sequence identical to human miR-34a and b) a separate complementary strand comprising a sequence that is 100% complementary to the human miR-34a sequence and at least one chemical modification at the 5′
end that enhances uptake of the active strand,wherein the human cancer cells are lung cancer cells, cancerous T cells, prostate cancer cells, or skin cancer cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method for reducing cell viability of human cancer cells comprising providing miRNA function to the cells by introducing into the cells a synthetic double-stranded RNA molecule 22-30 residues in length comprising:
-
a) an active strand comprising a sequence identical to human miR-34a and b) a separate complementary strand comprising i) a sequence that is 100% complementary to the human miR-34a sequence and ii) a 5′
blocking agent that enhances uptake of the active strand,wherein the human cancer cells are lung cancer cells, cancerous T cells, prostate cancer cells, or skin cancer cells. - View Dependent Claims (13, 14, 15, 16, 17)
-
Specification